Cmpx stock forecast.

Their AMPX share price targets range from $10.00 to $14.00. On average, they anticipate the company's stock price to reach $12.33 in the next twelve months. This suggests a possible upside of 173.5% from the stock's current price. View analysts price targets for AMPX or view top-rated stocks among Wall Street analysts.

Cmpx stock forecast. Things To Know About Cmpx stock forecast.

The 6 analysts offering 1 year price forecasts for CMPX have a max estimate of — and a min estimate of —. Analyst rating Based on 6 analysts giving stock ratings to CMPX in …Are you tired of spending countless hours manually tracking your inventory? Are you looking for a way to improve your decision making and forecasting processes? Look no further than a free inventory tracking template.Compx International Inc: A High-Performing Stock with a GF Score of 93. GF Score analysis. Find the latest CompX International Inc. (CIX) stock quote, history, news and other vital information to ... See the latest Compass Therapeutics Inc Ordinary Shares stock price (NASDAQ:CMPX), related news, valuation, dividends and more to help you make your investing decisions.Get actionable alerts from top Wall Street Analysts. Find out before anyone else which stock is going to shoot up. Get powerful stock screeners & detailed portfolio analysis. Subscribe Now See Plans & Pricing. Get the latest Apexigen APGN Stock forecast and financial predictions, including earnings and sales forecast, on TipRanks.com.

Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Compass Minerals International Inc have a median target of 43.50, with a high estimate of 82.00 and a low estimate of 36. ...66.07%. Get the latest Compass Therapeutics Inc. (CMPX) real-time quote, historical performance, charts, and other financial information to help you make more informed …

Track Compass Therapeutics Inc (CMPX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsView the latest CMPX earnings date, analysts forecasts, earnings history, and conference call transcripts. Skip to main content. S&P 500 4,594.63. DOW 36,245.50. QQQ 389.94. ... Stock Ideas and …

Safe & Green Development Corp. $1.95. -0.70. -26.42%. COMP | A complete NASDAQ Composite Index index overview by MarketWatch. View stock market news, stock market data and trading information. PSTX Stock 12 Months Forecast. $12.25. (369.35% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Poseida Therapeutics in the last 3 months. The average price target is $12.25 with a high forecast of $15.00 and a low forecast of $8.00. The average price target represents a 369.35% change from the last price of $2.61.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Previous Close $3.68. Volume 32.29K. Average Volume (3M) 157.25K. Market Cap. $1.22B. Enterprise Value $963.30M. Total Cash (Recent Filing) $259.49M. Total Debt (Recent Filing) $921.00K. Price to Earnings (P/E) -5.0.

About Compass Therapeutics. Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth.

Dec 1, 2023 · The average twelve-month price prediction for Compass Therapeutics is $9.33 with a high price target of $10.30 and a low price target of $8.00. Learn more on CMPX's analyst rating history. Do Wall Street analysts like Compass Therapeutics more than its competitors?

Check if CMPS Stock has a Buy or Sell Evaluation. CMPS Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Compass Pathways PLC News.See the latest Compass Therapeutics Inc Ordinary Shares stock price (NASDAQ:CMPX), related news, valuation, dividends and more to help you make your investing decisions.We would like to show you a description here but the site won’t allow us.Great weather can motivate you to get out of the house, while inclement weather can make you feel lethargic. When the weather’s great we want to be outside enjoying it. For the best regional weather forecasts check out AccuWeather.The average Cabaletta Bio stock price prediction forecasts a potential upside of 75.22% from the current CABA share price of $18.67. What is CABA's forecast return on ...Most recent stock forecast was given on BGNE, BeiGene, Ltd at 26-Jun-2023 ... CMPX GLUE TNGX TPTX Turning Point Therapeutics NRIX Nurix Therapeutics COGT ...Overview News Ideas Financials Technicals Forecast CMPX chart Today 2.59% 5 days 2.06% 1 month 3.66% 6 months −31.25% Year to date −61.10% 1 year −34.44% 5 years …

Are you tired of spending countless hours manually tracking your inventory? Are you looking for a way to improve your decision making and forecasting processes? Look no further than a free inventory tracking template.PAYO Stock 12 Months Forecast. $8.80. (56.58% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Payoneer in the last 3 months. The average price target is $8.80 with a high forecast of $10.00 and a low forecast of $8.00. The average price target represents a 56.58% change from the last price of $5.62. According to the issued ratings of 6 analysts in the last year, the consensus rating for Mesoblast stock is Hold based on the current 1 sell rating, 3 hold ratings and 2 buy ratings for MESO. The average twelve-month price prediction for Mesoblast is $7.13 with a high price target of $17.00 and a low price target of $1.50.Jul 30, 2021 · In many cases to predict stock price, gold and crude oil have been used as extra indicators [36], in some of the works, 43 technical indicators as input features along with LSTM to forecast price ... Website. 2014. 26. Tom Schuetz. https://www.compasstherapeutics.com. Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company’s product candidates include CTX-009, a bispecific antibody that blocks Delta …View the full NASDAQ Composite Index (COMP.US) index overview including the latest stock market news, data and trading information.

According to our current CMPX stock forecast, the value of Compass Therapeutics shares will drop by -2.77% and reach $ 1.497361 per share by November 19, 2023. According to …Compass Therapeutics Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction. ... CMPX Related stocks. Symbol 3M %Chg ; CMPX +4.67% : Compass Therapeutics ...

Back to CMPX Overview. *The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once ... This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of ...NSD:CMPX Detailed Stock Analysis, Stock Price Forecasts, Analyst Ratings, Financial Analysis, Stock News & Historic QuotesGas prices are at a record high, and experts are forecasting that prices could go higher this summer — perhaps $5 or even over $6 a gallon. By clicking "TRY IT", I agree to receive newsletters and promotions from Money and its partners. I a...CMPX Nasdaq Stock Market • delayed by 15 minutes • CURRENCY IN USD • Biotechnology & Medical Research. Compass Therapeutics, Inc. (CMPX) Compare. Compass Therapeutics, Inc. 2.84 ...It follows that stock’s current price would drop -591.82% in reaching the projected high whereas dropping to the targeted low would mean a loss of -403.14% for stock’s current value. Compass Therapeutics Inc (CMPX) estimates and forecastsSee CAPITAL POWER CORPORATION stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. ... Forecast . Price target. 44.85 0.00 0.00%. The 10 analysts offering 1 year price forecasts for CPX have a max estimate of — and a min estimate of —.What is the difference between Tesla's targeted high price and its latest price? ... Stock comparison. Financial metrics over time. Search other exchanges. News ...

Compx International Inc: A High-Performing Stock with a GF Score of 93. GF Score analysis. Find the latest CompX International Inc. (CIX) stock quote, history, news and other vital information to ...

March 7, 2024. EPS forecast (this quarter) $0.30. Annual revenue (last year) $378.5M. Annual profit (last year) $18.7M. Net profit margin.

The Compx International, Inc. - Class A stock forecast is 40.29786370896 USD for 2024 November 25, Monday; and 148.757 USD for 2028 November 25, Saturday with technical analysis. Compx International, Inc. - Class A (CIX) stock price prediction is 40.29786370896 USD.Track COMPASS Pathways (CMPS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Compass Therapeutics, Inc. (CMPX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 1.6500 -0.0700 (-4.07%) At close: 04:00PM EST 1.6500 0.00 …Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Compass Minerals International Inc have a median target of 43.50, with a high estimate of 82.00 and a low estimate of 36. ...This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of ...Stock Price Forecast. The 5 analysts offering 12-month price forecasts for CompoSecure Inc have a median target of 13.00, with a high estimate of 15.00 and a low estimate of 7.00. The median ...Nov 23, 2022 · Stock Screener; ETF Screener; Comparisons; Explore Alpha Picks ... Compass Therapeutics (CMPX) Investor Presentation - Slideshow. Nov. 23, 2022 6:22 AM ET Compass Therapeutics, Inc. (CMPX) SA ... Compass Therapeutics Inc. (CMPX) stock is trading at $3.76 as of 3:42 PM on Friday, Jan 20, a gain of $0.01, or 0.27% from the previous closing price of $3.75. Volume today is above average. So far 918,164 shares have traded compared to average volume of 271,877 shares. The stock has traded between $3.20 and $3.88 so far today.Dec 1, 2023 · 4 brokers have issued twelve-month target prices for Catalyst Pharmaceuticals' stock. Their CPRX share price targets range from $24.00 to $27.00. On average, they predict the company's stock price to reach $24.75 in the next twelve months. This suggests a possible upside of 67.0% from the stock's current price. View NASDAQ COMPOSITE COMPX investment & stock information. Get the latest NASDAQ COMPOSITE COMPX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.

FCEL Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for Fuelcell Energy in the last 3 months. The average price target is $1.65 with a high forecast of $2.00 and a low forecast of $1.00. The average price target represents a 35.25% change from the last price of $1.22.Get free stock tools, free stock ratings, free stock charts and calculate the value of stocks to buyGLTO Stock 12 Months Forecast. $5.67. (808.65% Upside) Based on 4 Wall Street analysts offering 12 month price targets for Galecto in the last 3 months. The average price target is $5.67 with a high forecast of $10.00 and a low forecast of $2.00. The average price target represents a 808.65% change from the last price of $0.62.Based on analysts offering 12 month price targets for CMPX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Instagram:https://instagram. best private investment platformstop self directed ira companiesbest financial magazine for beginnersaiko solar CMPX stock forecast Our latest prediction for Compass Therapeutics Inc's stock price was made on the March 15, 2023 when the stock price was at 3.56$. In the short term (2weeks), CMPX's stock price should underperform the market by -2.94%. During that period the price should oscillate between -8.72% and +5.46%. Analyst Forecast. According to 4 analysts, the average rating for CMPX stock is "Strong Buy." The 12-month stock price forecast is $9.33, which is an increase of 452.07% from the latest price. dental plans in georgiahow to buy gold on webull Compass Therapeutics Inc. (CMPX) stock has fallen -6.02% while the S&P 500 is higher by 0.38% as of 3:09 PM on Thursday, May 18. CMPX has fallen -$0.19 from the previous closing price of $3.24 on volume of 185,132 shares. Over the past year the S&P 500 is up 6.40% while CMPX is higher by 23.48%. CMPX lost -$0.36 per share the over …Back to CMPX Overview. *The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once ... megaworld The consensus estimate for Capital Power’s current full-year earnings is $3.23 per share. Raymond James also issued estimates for Capital Power’s Q2 2024 earnings at $0.89 EPS, Q3 2024 earnings at $1.61 EPS, Q4 2024 earnings at $1.17 EPS and FY2024 earnings at $5.27 EPS. Several other research analysts have also weighed in on the stock.Track Cidara Therapeutics Inc (CDTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsCompass Therapeutics. Compass Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Its pipeline product candidates are CTX-471/ CD137 agonist and CTX-8371.